ORDER Granting in Part and Denying in Part Patent Owner’s Unopposed Motion to Expunge | Dec 16, 2024 | PAPER | BOARD |
Patent Owner's Motion to Expunge | Nov 26, 2024 | PAPER | PATENT OWNER |
Termination Decision: Post-DI dismissal | Oct 15, 2024 | PAPER | BOARD |
Other: Fed Circuit mandate | May 31, 2024 | PAPER | BOARD |
Other: other court decision | May 31, 2024 | PAPER | BOARD |
Patent Owner's Notice of Appeal | Sep 26, 2022 | PAPER | PATENT OWNER |
Rehearing: Decision on Request for Rehearing | Jul 26, 2022 | PAPER | BOARD |
Order: Panel Change Order | Jun 21, 2022 | PAPER | BOARD |
Order: Order Denying POP Request | Feb 17, 2022 | PAPER | BOARD |
Final Written Decision: original | Jan 20, 2022 | PAPER | BOARD |
E-Mail Requesting POP Review | Jan 7, 2022 | EXHIBIT | BOARD |
Notice: notice of receipt of POP request | Jan 7, 2022 | PAPER | BOARD |
Patent Owner's Request for Rehearing | Jan 6, 2022 | PAPER | PATENT OWNER |
Final Written Decision: Determining All Challenged Claims Unpatentable 35 U.S.C. § 318(a) | Dec 7, 2021 | PAPER | BOARD |
Exhibit 3001 | Dec 7, 2021 | EXHIBIT | BOARD |
Other: Hearing transcript | Nov 12, 2021 | PAPER | BOARD |
Petitioner's Demonstrative Exhibits | Aug 9, 2021 | EXHIBIT | PETITIONER |
Patent Owner's Updated Exhibit List | Aug 9, 2021 | PAPER | PATENT OWNER |
Patent Owner's Demonstratives | Aug 9, 2021 | EXHIBIT | PATENT OWNER |
ORDER
Setting Oral Argument | Jul 21, 2021 | PAPER | BOARD |
Patent Owner's Sur-Reply | Jul 8, 2021 | PAPER | PATENT OWNER |
Petitioner's Request for Oral Argument | Jul 1, 2021 | PAPER | PETITIONER |
Patent Owner's Request for Oral Argument | Jul 1, 2021 | PAPER | PATENT OWNER |
Public Version Petitioner's Reply | Jun 24, 2021 | PAPER | PETITIONER |
Public Version Stahl Deposition Transcript | Jun 24, 2021 | EXHIBIT | PETITIONER |
Public Version Reisetter Deposition Transcript | Jun 24, 2021 | EXHIBIT | PETITIONER |
Certificate of Service | Jun 24, 2021 | PAPER | PETITIONER |
Petitioner's Motion to Seal | Jun 10, 2021 | PAPER | PETITIONER |
EXPUNGED | Jun 10, 2021 | PAPER | PETITIONER |
Supplemental Declaration Dr. Kosten, M.D. | Jun 10, 2021 | EXHIBIT | PETITIONER |
Claim Construction Brief in District Court | Jun 10, 2021 | EXHIBIT | PETITIONER |
Claim Construction Brief at Federal Circuit | Jun 10, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 10, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Jun 10, 2021 | EXHIBIT | PETITIONER |
Morrison | Jun 10, 2021 | EXHIBIT | PETITIONER |
Notice of Depositions Drs. Reisetter and Stahl | Apr 22, 2021 | PAPER | PETITIONER |
Patent Owner's Updated Mandatory Notices | Apr 19, 2021 | PAPER | PATENT OWNER |
Petitioner's Objections to Exhibits to Patent Owner's Response | Mar 18, 2021 | PAPER | PETITIONER |
Patent Owner's Motion to Seal | Mar 11, 2021 | PAPER | PATENT OWNER |
Patent Owner's Response | Mar 11, 2021 | PAPER | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | PAPER | PATENT OWNER |
FDA Atypical Antipsychotic Drugs Information | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Franklin, Lurasidone for the treatment of bipolar depression an evidence-based review | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Shayegan et al., Atypical Antipsychotics Matching Receptor Profile to Individual Patient's Clinical Profile | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Kane et al. Clozapine for the Treatment-Resistant Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Nashed et al., Olanzapine-Induced Weight Gain in Patients with
Bipolar I Disorder A Meta-Analysis | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Symbyax�� Label | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Seroquel Label | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Lieberman et al., Effectiveness of Antipsychotic Drugs in Patients
with Chronic Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Thase, Quetiapine monotherapy for bipolar depression | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Hoyberg et al., Risperidone versus perphenazine in the treatment of
chronic schizophrenic patients with acute exacerbations | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Lombardo et al., Two 6-Week, randomized, Double-Blind, Placebo-
Controlled Studies of Ziprasidone in Outpatients with Bipolar I
Depression | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Sachs et al., Efficacy and Safety of Adjunctive Oral Ziprasidone for
Acute Treatment of Depression in Patients With Bipolar I Disorder | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Pacher et al., Cardiovascular Side Effects of New Antidepressants and
Antipsychotics | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Stimmel at al., Ziprasidone An Atypical Antipsychotic Drug for the
Treatment of Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Fala, Latuda (Lurasidone HCL) Receives 2 New Indications for Use
in Bipolar Depression as Monotherapy and as Adjunctive Therapy with
Lithium or Valproate | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Meltzer et al., Lurasidone in the Treatment of Schizophrenia A
Randomized, Double-Blind, Placebo- and Olanzapine-Controlled
Study | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Correll et al., Effects of Olanzapine Combined With Samidorphan on
Weight Gain in Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Reiffen et al., Generic Drug Industry Dynamics | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
DiMasi et al. The price of innovation new estimates of drug
development costs | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Samalin et al., Clinical potential of lurasidone in the management of
schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Latuda Product Monograph | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
O���Day et al., Long-term cost-effectiveness of atypical antipsychotics
in the treatment of adults with schizophrenia in the U.S | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Dainippon Sumitomo Pharma Co., Ltd., Supplementary Financial Data
for Year Ended March 31, 2014 | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Jancin, Newer Atypical Antipsychotics Draw Praise | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Albright, Three key antipsychotics lose patent protection | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Pareek, Factors Affecting Non-Compliance to Psychotropic Drugs of
Patients with Psychosis as Perceived by their Family Members
Attending the Psychiatric Outpatient Department at Selected Hospital,
Mangalore | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Ng-Mak et al., Patient Preferences for Important Attributes of Bipolar
Depression Treatments | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Ng-Mak et al., Efficacy and Metabolic Effects of Lurasidone Versus
Brexpiprazole in Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Rajagopalan et al., Cost-Utility Analysis of Lurasidone Versus
Aripiprazole in Adults with Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Mattingly et al., Switching to Lurasidone Following 12 Months of
Treatment with Risperidone | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Mak et al., Cost Savings Associated with Improved Adherence Among
Patients with Schizophrenia Using Lurasidone | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Comparison of Atypical Antipsychotics | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Poyurovsky et al., Attentuation of Olanzapine-Induced Weight Gain
in Patients with Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Poyurovsky et al., Attentuating Effect of Reboxetine on Appetite and
Weight Gain in Olanzapine-Treated Schizophrenia Patients | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Zhuo et al., Topiramate and Metformin Are Effective Add-On
Treatments in Controlling Anti-Psychotic Weight Gain | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Declaration of Dr. Stephen Stahl | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Declaration of Scott Stancell-Condron | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Dr. Thomas Kosten | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Hummel et al., Clozapine as Add-On Medication in the Maintenance
Treatment of Bipolar and Schizoaffective Disorder | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
McElroy et al., Pharmacologic Agents for the Treatment of Acute
Bipolar Mania | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Weiden, Partial Compliance and Risk of Rehospitalization Among
California Medicaid Patients with Schizophrenia, Psychiatric
Services | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
Tohen et al., Am J. Psychiatry | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
M��ller, J. Clin. Psych | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
News Release: FDA Approves Once-Daily Latuda (lurasidone
HCl) for Treatment of Patients with Schizophrenia | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
News Release Sunovion Pharmaceuticals Inc. Announces FDA
Approval of Latuda (lurasidone HCl) as Monotherapy and
Adjunctive Therapy in Adult Patients with Bipolar Depression | Mar 11, 2021 | EXHIBIT | PATENT OWNER |
PANEL CHANGE ORDER
Conduct of the Proceedings
37 C.F.R. �� 42.5 | Mar 2, 2021 | PAPER | BOARD |
Patent Owner's Notice of Deposition of Thomas R. Kosten, M.D. | Jan 29, 2021 | PAPER | PATENT OWNER |
Objections to Evidence Filed with Preliminary Response | Dec 23, 2020 | PAPER | PETITIONER |
Joint Stipulation to Modify Due Dates 1, 2 and 3 | Dec 14, 2020 | PAPER | PATENT OWNER |
Granting Institution of Inter Partes Review | Dec 9, 2020 | PAPER | BOARD |
SCHEDULING ORDER | Dec 9, 2020 | PAPER | BOARD |
History of the discovery and clinical introduction of chlorpromazine | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
ZYPREXA (olanzapine) Label (2000) | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Excess Early Mortality in Schizophrenia | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Complaint filed 2/23/2018 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Novel antipsychotics | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Diagnostic and Statistical Manual of Mental Disorders - Part 2 of 2 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Antipsychotic-Induced Weight Gain | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Patent Owner's Preliminary Response | Sep 18, 2020 | PAPER | PATENT OWNER |
ABILIFY (aripiprazole) Label (2002) | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
LATUDA (lurasidone) Label (2018) | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Premature Mortality Among Adults with Schizophrenia in the United States | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Complaint filed 2/13/2018 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Complaint filed 8/31/2018 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Complaint filed 9/12/2018 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Complaint filed 10/09/2018 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Sumitomo Dainippon Pharma Announces Resolution of Disputes Under Consolidated Patent Infringement Lawsuit Regarding ANDAs for Latuda in the U.S. | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Treatment of Schizophrenia and Spectrum Disorders | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Iloperidone, Asenapine and Lurasidone | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Diagnostic and Statistical Manual of Mental Disorders - Part 1 of 2 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
A Short History of Bipolar Disorder | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Diagnostic and Statistical Manual of Mental Disorders | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Second-Generation (Atypical) Antipsychotics and Metabolic Effects | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Weight Gain from Novel Antipsychotic Drugs | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Risperdal Label | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Attachment 1 Ziprasidone | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Antipsychotics | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Stahl's Essential Psychopharmacology | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
The Pharmacology of Weight Gain with Antipsychotics | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Notice of allowance mailed 8/13/15 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
The 5-HT2C receptor and antipsychotic induced weight gain | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Schizophrenia Symptoms, Patterns and Statistics and Patterns | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Mental Health | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Geodon Label - Part 1 of 2 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Geodon Label - Part 2 of 2 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Weight Gain, Antipsychotic Drug Treatment and Pharmacogenomics | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Lurasidone | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
U.S. Patent No. 6,964,962 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
U.S. Patent Pub. No. 2001/0047010 | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Seroquel XR | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Novel Antipsychotics | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Weight Change and Antipsychotic Treatment in Patients with Schizophrenia | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Certified Translation of Horisawa et al. | Sep 18, 2020 | EXHIBIT | PATENT OWNER |
Notice of Accord Filing Date | Jun 18, 2020 | PAPER | BOARD |
Patent Owner's Mandatory Notices | Jun 18, 2020 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Jun 18, 2020 | PAPER | PATENT OWNER |
Power of Attorney | Jun 5, 2020 | PAPER | PETITIONER |
Petition for Inter Partes Review US 9815827 | Jun 5, 2020 | PAPER | PETITIONER |
EX-1001, U.S. Patent No. 9,815,827 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1002, Declaration of Dr. Thomas Kosten, M.D. | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1004, Priority Application | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1008, Loebel | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1010, Preliminary Amendment in Priority Application (Feb. 18, 2005) | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1011 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1013 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1014 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1016 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1017 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1020 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1003, The '827 Patent Application | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1005, Provisional Application | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1006, Preliminary Amendment in the '827 Patent Application
(October 5, 2015) ("Second Preliminary Amendment") | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1007, Latuda(R) Information | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1009, U.S. Patent No. 5,532,372 ("Saji Patent") | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1012 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1015, Declaration of Masaaki Ogasa in Priority Application (June17, 2008) | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1018 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1019, U.S. Patent No. 9,174,975 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1024, DSM-5 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1021 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1022, DSM-IV | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1023, DSM-IV TR | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1025 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1026, Saji Amendment | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1027, Saji March 1993 Amendment | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1028, Horisawa, with translation from Japanese to English | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1030, ICH-4 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1032, European Patent No. 0,464,846, Saji EP '846 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1033 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1034 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1036, Declaration of Sylvia D. Hall-Ellis, Ph.D. ("Librarian's
Affidavit") | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1037, Latuda Label 2012 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1039, Olanzapine 2001 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1040, WO 01/76557 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1041, Allison | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1044, Caccia | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1047 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1029 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1031, Federal Register Dose Optimization Guidelines 1994 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1035, June 2013 Press Release | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1038, Latuda Label July 2013 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1042, Wetterling | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1046, File History from PAIR for the '827 Patent Application | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1049 | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1050, Petitioner's limitation by limitation Claim Listing for the
'827 Patent | Jun 5, 2020 | EXHIBIT | PETITIONER |
EX-1048, Saji Application | Jun 5, 2020 | EXHIBIT | PETITIONER |